Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Turnstone Biologics Corp. - Common Stock (NQ: TSBX )

0.5885 -0.0567 (-8.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Turnstone Biologics Corp. - Common Stock

< Previous 1 2 Next >
Crude Oil Gains Over 1%; Alibaba Posts Weak Revenue
Via Benzinga
Exposures Fossil Fuels
Nasdaq Jumps Over 2%; Walmart Earnings Top Views
Via Benzinga
Turnstone Biologics Shifts Focus To 'High Unmet Medical Need' Cancers, Shares Initial Data From Colorectal Cancer Cell Therapy Study
Turnstone Biologics stock drops after Phase 1 STARLING trial data reveals mixed results for TIDAL-01 in metastatic colorectal cancer, with a 25% response rate. 
Via Benzinga
Dow Surges Over 500 Points; US Retail Sales Rise In July
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Turnstone Biologics (TSBX) Stock Down 38% Today?
Turnstone Biologics stock is down on Thursday as TSBX investors react to the company missing estimates for Q2. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news today! 
Via InvestorPlace
Why Lumentum Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Via Benzinga
TSBX Stock Earnings: Turnstone Biologics Misses EPS for Q2 2024
TSBX stock results show that Turnstone Biologics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
From Turnstone Biologics Corp.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
TSBX Stock Earnings: Turnstone Biologics Misses EPS for Q1 2024
TSBX stock results show that Turnstone Biologics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Appoints William Waddill to its Board of Directors
From Turnstone Biologics Corp.
Via GlobeNewswire
TSBX Stock Earnings: Turnstone Biologics Beats EPS for Q4 2023
TSBX stock results show that Turnstone Biologics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights
From Turnstone Biologics Corp.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Turnstone Biologics to Participate in Upcoming Investor Conferences
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.
From Turnstone Biologics Corp.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Turnstone Biologics Corp.
Via GlobeNewswire
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
From Turnstone Biologics Corp.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Turnstone Biologics Corp.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber
Internationally recognized thought leader with extensive experience in innovative immunotherapies for solid tumors will help guide Turnstone’s continued advancement of its Selected TIL therapies 
From Turnstone Biologics Corp.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.